NCT02195323

Autologous Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)

Administration of Autologous Bone Marrow Mesenchymal Stem Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Royan Institute · Other Government
• Sex: All
• Age: 25 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This study was designed to provide confirmation of safety of mesenchymal stem cells (MSCs) therapy in chronic kidney disease (CKD).

Detailed description

We will assess the 18-month safety and potential efficacy of autologous MSCs as a therapy for CKD. A total of 10 patients with CKD IV injection of high doses 2×106/kg of autologous MSCs t, which will be derived from biopsies of their bone marrow. Assessments will be performed at 1, 3, 6, 12 and 18 months after cell injection. Changes in Glomerular Filtration Rate (GFR) were evaluated by scan isotope.

Conditions

• Chronic Kidney Disease

Interventions

Type	Name	Description
BIOLOGICAL	Intravenous injection	Intravenous injection of bone marrow derived MSC in patients with CKD.

Timeline

• Start date: 2014-04-01
• Primary completion: 2015-12-01
• Completion: 2016-01-01
• First posted: 2014-07-21
• Last updated: 2016-01-05

Locations

1 site across 1 country: Iran